Canbex Therapeutics Ltd
Canbex is developing a validated platform of novel small molecule compounds that selectively regulate excitability in neuronal and endothelial cells via BKCa, with applications in movement disorders, glaucoma, epilepsy, pain and others including the orphan paediatric disorder Fragile X Syndrome.
The Canbex proprietary VSN compounds are activators of the BKCa large conductance potassium channel. The company's lead BKCa activator, VSN16R, is in Phase II for the treatment of spasticity in people with multiple sclerosis, an important and poorly served indication. The Phase II trial of VSN16R for spasticity in MS is being carried out under an option agreement with Ipsen SA, which aims to add VSN16R to its growing portfolio of spasticity treatments.
Dr Keith PowellChairman
Dr Jesse SchulmanCEO
CatSci Ltd is a problem-solving chemistry CRO supporting the research, development and manufacture of materials for the life science and wider chemistry-using industries, with a strong scientific pedigree, large pharma background and track record of delivering successful projects.
We provide solutions based on our unique combination of computational, statistical, analytical, and synthetic chemistry plus our applied catalysis expertise. In particular, CatSci specialises in the custom synthesis of small molecule NCEs, APIs and advanced intermediates.
CatSci is well placed to meet the needs of discovery and early development chemistry, including new route design and assessment, reaction development, material supply from the mg scale up to 1 kg non-GMP, including the synthesis of air-, moisture- and heat-sensitive compounds.
A full list of our services can be found at www.catsci.com/services.
Better Chemistry for Better Products!
Dr Simon TylerCommercial Director
Dr Ross BurnGeneral Manager
Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in all phases of oncology, hematology and a range of other therapeutic areas (respiratory, ophthalmology, dermatology, etc.), together with global sourcing and functional service provider (FSP) solutions. Chiltern’s 3.700 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
Dr Jan de WittVice President, Medical Affairs
Ms Andrea Cotton-BerryGlobal Director, Client Services
Ms Frances MurphyClient Services Director
Mrs Ivana GaljerClient Services Director
Mr John O'BrienSenior Account Director
Ms Birgit MundExecutive Director, Business Development
Ms Juliette AlmondDirector, Client Services
Ms Blanca TrascasaAccount Manager
Mr Qaisar RafiqDirector, Business Development
CIMYM BioSciences was established to develop oncology and immunological therapeutics. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care. CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.
Ms Yvonne KennardCEO
Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.
CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.
BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.
CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Paul CroninDirector, Business Development
Crescendo Biologics Ltd
Crescendo Biologics is focused on the discovery and development of best-in-class Humabody™ VH fragment therapeutics, using its novel transgenic platform. Crescendo is enabling the major VH product formats (multivalent, half-life-extended and topical) for its own pipeline, focused in oncology (immuno-oncology, checkpoint inhibitor and ADC, Humabody Drug Conjugate programmes) and inflammation, and to make it the partner of choice for human VH fragment therapeutics.
Dr Nigel CrockettHead of Business Development
Dr Peter PackCEO
Curileum Discovery Ltd
Curileum Discovery Ltd is an new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.
With access to a large supply of patient tissues and leading clinical collaborators, we can rapidly test hypotheses on defined patient populations to discover and support target development for therapeutics and molecular diagnostics.
We have a proven track record of delivery along with streamlined business, legal, and project management capabilities in our discovery and development partnerships with pharmaceutical companies.
Dr Jeffrey MooreCEO
Custom Pharmaceuticals is a contract development and manufacturing organisation providing formulation development, contract manufacturing and packaging services to an international client base within the pharmaceutical industry for clinical and commercial solid oral dosage products. Areas of specialty are in hormones, controlled substances and extended/modified release based formulations.